Board of Directors

Andrew Sandham, (Chairman)
Lawrence Bloch, MD, JD
David Brand
Aaron Davidson
Kenneth Galbraith
Jonathan R. Goodman
Deepa Pakianathan, PhD
Samuel P. Wertheimer, PhD

Leadership

Management Team
Board of Directors
Board Observers
Scientific Advisory Board

Lawrence Bloch, MD, JD, CEO, NeurAxon Inc.

Led private, IPO and follow-on equity financings while serving as CFO and head of business development at Applied Molecular Evolution (AME) and NitroMed.  Negotiated multiple corporate deals including the AME merger with Eli Lilly and Company.  Dr Bloch earned a J.D. from Harvard Law School, MD from Harvard Medical School and MBA from Harvard Business School.